Categories: News

Lightview Capital Announces Sale of Array

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

WEST PALM BEACH, Fla., Aug. 9, 2024 /PRNewswire/ — Lightview Capital (Lightview), a leading lower middle market private equity firm announces the sale of Array to WCG, a global leader in clinical research solutions.

Founded in 2003, Array is a leading content engagement partner for life sciences events that offers a unique combination of data, technology, and engagement services proven to enhance business results and drive actionable insights. The company has been a part of Lightview Capital’s portfolio since 2019, when the private equity firm made a significant investment to enhance Array’s growth and expansion.

Under Lightview’s ownership, Array has enhanced its proprietary technology, expanded its meeting delivery capabilities from in-person to virtual and hybrid meeting types, and further cemented its position as a trusted technology partner for the life science industry.

Marc Crawford, CEO of Array, commented, “Our partnership with Lightview Capital has been instrumental in our growth journey. We are excited to join WCG and continue the mission of improving lives by accelerating clinical research.”

“We are pleased to announce the successful sale of Array to WCG,” said Conor Mullett, Managing Director at Lightview Capital. “This transaction represents a significant milestone for both Array and Lightview, showcasing our ability to build and scale market-leading platforms in the business services and tech-enabled services sectors.”

Union Square Advisors and Madison Park Group served as co-lead financial advisors and DLA Piper served as legal advisor to Lightview and Array in connection with this transaction.

About Lightview Capital:

Lightview Capital is a leading private equity firm focused on investing in founder-owned companies in the business services and tech-enabled services industries. Lightview partners with its portfolio companies by providing deep industry knowledge, insightful experience, and active resources to unlock growth and drive value. Lightview Capital’s approachable investment style combines deep operational and financial experience with an entrepreneurial spirit that delivers measurable results. For more information, visit lightviewcapital.com.

About Array

Array is a content engagement partner for life sciences events – with over 20 years’ experience at over 10,000 events. Array’s unique combination of technology and services is proven to improve business results by engaging more than 90% of audience members and increasing knowledge transfer while collecting meaningful analytics down to the individual participant level for actionable insights. Array combines technical support, event production expertise, and analytics interpretation and guidance to maximize the impact of in-person, virtual, and hybrid life sciences events. For more information about Array, please visit arraylive.com.

Contacts for Lightview Capital

Laurel Vermette

Lvermette@lightviewcapital.com

Contacts for Array

Marc Crawford

mcrawford@arraylive.com

View original content:https://www.prnewswire.com/news-releases/lightview-capital-announces-sale-of-array-302218844.html

SOURCE Lightview Capital

Staff

Recent Posts

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel…

17 hours ago

ISS Recommends Shareholders Vote FOR the Merger between Regional Health Properties, Inc. and SunLink Health Systems, Inc.

Atlanta, GA., July 25, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (“Regional”) (OTCBQ: RHEP)…

17 hours ago

PharmAla Issues Q3 Financial Statements

TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”)…

17 hours ago

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”)…

17 hours ago

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

DOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”)…

17 hours ago

IRADIMED CORPORATION to Hold Second Quarter of 2025 Financial Results Conference Call on August 1, 2025

ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the…

17 hours ago